<DOC>
	<DOC>NCT03017547</DOC>
	<brief_summary>Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.</brief_summary>
	<brief_title>A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>Up to 160 patients with ARDS will be randomized to receive either IC14 at a dosage of 4 mg/kg on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 or placebo for 4 days beginning within 48 hours of meeting inclusion criteria. Study participation will be for 28 days.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>1. ICU admission 2. Age 1870 years 3. Presence of a known ARDS clinical risk within 7 days of onset: 1. Pneumonia 2. Sepsis 3. Trauma 4. Aspiration 5. Pancreatitis 4. Presence of ARDS (per Berlin criteria) defined as follows: 1. Acute onset (&lt;48 hours) 2. PaO2/FiO2&lt;300 on PEEP≥5 3. Bilateral opacities consistent with pulmonary edema on frontal chest radiograph not fully explained by effusions, lobar/lung collapse, or nodules. 4. Requirement for positive pressure ventilation via endotracheal tube 5. Anticipated duration of mechanical ventilation &gt;48 hrs 1. Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry 2. Intubation for cardiopulmonary arrest 3. Donotattempt resuscitation (DNAR) status 4. Intubation for status asthmaticus, pulmonary embolus, myocardial infarction 5. Anticipated survival &lt;48 hours from intubation 6. Anticipated survival &lt;28 days due to preexisting medical condition 7. Significant preexisting organ dysfunction 1. Lung: Currently receiving home oxygen therapy as documented in medical record 2. Heart: Preexisting congestive heart failure defined as an ejection fraction &lt;20% as documented in the medical record 3. Renal: Chronic renal failure requiring renal replacement therapy 4. Liver: Severe chronic liver disease defined as ChildPugh Class C 8. Preexisting, ongoing immunosuppression 1. Solid organ transplant recipient 2. Chronic highdose corticosteroids (equivalent to &gt;20 mg/prednisone/day for &gt;14 days in the last 30 days) 3. Oncolytic drug therapy within the past 14 days 4. Known HIV positive with CD4 count &lt;200 cells/mm3 9. Current treatment with Enbrel® (etanercept), Remicade® (infliximab), Humira® (adalimumab), Cimzia® (certolizumab), or Simponi® (golimumab), Kineret® (anakinra), or Arcalyst® (rilonacept) 10. Pregnancy 11. History of hypersensitivity or idiosyncratic reaction to IC14 12. Deprivation of freedom by administrative or court order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>